IBS News

Subscribe to IBS News feed
IBS Patient Support Group - IBSpatient.org - IBS News
Updated: 3 min 47 sec ago

Pubmed-ABC om - IBS – irritabel tarm.

Jan 10, 2019
ABC om - IBS – irritabel tarm. Lakartidningen. 2018 03 07;115: Authors: Lagerlöf E, Agreus L, Simrén M, Törnblom H PMID: 29533415 [PubMed - indexed for MEDLINE] View the full article

Pubmed-Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.

Jan 10, 2019
Related Articles Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019 Jan 04;20(1): Authors: Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A, Krzystek-Korpacka M Abstract Nicotinamide phosphoribosyltransferase's (Nampt) association with inflammatory bowel disease (IBD) is unclear. The study was aimed at unraveling Nampt's clinical and diagnostic relevance. The serum concentration (Luminex-xMAP® technology) was measured in 113 patients with Crohn's disease (CD), 127 with ulcerative colitis (UC) and 60 non-IBD controls: 40 healthy individuals and 20 with irritable bowel syndrome (IBS). The leukocyte (44 CD/37 UC/19 IBS) and bowel expression (186 samples) was also evaluated (RT-qPCR). All were referred to IBD phenotype, activity, treatment, and inflammatory/nutritional/angiogenic/hypoxia indices. Serum-Nampt and leukocyte-Nampt were positively correlated and were more elevated in active-IBD than in IBS, with leukocyte-Nampt being a fair differential marker. Serum-Nampt in UC positively correlated with its clinical and endoscopic activity as well as with pro-inflammatory cytokines. Serum-Nampt ≤1.54 ng/mL was a good indicator of mucosal healing. The expression of Nampt was up-regulated both in inflamed and quiescent colon and reflected, similarly to leukocyte-Nampt, the clinical activity of IBD. Bowel-Nampt was independently associated with IL1B and hypoxia-inducible factor 1α (HIF1A) expression in inflamed bowel but with FGF2 expression in quiescent bowel. In summary, Nampt's elevation in IBD at local and systemic levels, and protein and mRNA levels, reflects IBD activity and is associated with inflammation, hypoxia (active) and tissue repair (inactive disease). PMID: 30621173 [PubMed - in process] View the full article

Pubmed-The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study.

Jan 10, 2019
Related Articles The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study. Gastroenterol Res Pract. 2018;2018:8791916 Authors: Lee SH, Joo NS, Kim KM, Kim KN Abstract Backgrounds: Recent studies suggest that diarrhea-predominant irritable bowel syndrome (IBS) is associated with intestinal bacterial microflora, colonic inflammation, and small intestinal bacterial overgrowth (SIBO). The purpose of this study was to evaluate the effect of a multistrain probiotic intake on these associated factors in patients with diarrhea-predominant IBS. Methods: The recruited volunteers were adults who were diagnosed with diarrhea-predominant IBS according to the Rome III criteria. After 8 weeks of probiotic ingestion, changes in gastrointestinal symptoms, fecal microbiome, SIBO, and fecal calprotectin were determined. Results: There was an increase in beneficial bacteria (41.2 ± 16.8% vs. 53.7 ± 15.3%, P = 0.018) and a decrease in harmful bacteria (13.0 ± 13.9% vs. 4.7 ± 4.0%, P = 0.010) in the microbial stool analysis. The SIBO prevalence also decreased at the end of treatment. However, the average levels of fecal calprotectin showed a decreasing tendency, without reaching statistical significance (364.4 ± 729.1 mg/kg vs. 200.9 ± 347.6 mg/kg, P = 0.375). Conclusion: Treatment with a multistrain probiotic for 8 weeks led to significant increases in beneficial bacteria in the gut as well as the improvement of gastrointestinal symptoms. This study is registered at the Clinical Research Information Service (KCT0002906). PMID: 30622561 [PubMed] View the full article

Pubmed-Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms.

Jan 10, 2019
Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms. PLoS One. 2019;14(1):e0210064 Authors: Sanctuary MR, Kain JN, Chen SY, Kalanetra K, Lemay DG, Rose DR, Yang HT, Tancredi DJ, German JB, Slupsky CM, Ashwood P, Mills DA, Smilowitz JT, Angkustsiri K Abstract Over half of all children with autism spectrum disorders (ASD) have gastrointestinal (GI) co-morbidities including chronic constipation, diarrhea, and irritable bowel syndrome. The severity of these symptoms has been correlated with the degree of GI microbial dysbiosis. The study objective was to assess tolerability of a probiotic (Bifidobacterium infantis) in combination with a bovine colostrum product (BCP) as a source of prebiotic oligosaccharides and to evaluate GI, microbiome and immune factors in children with ASD and GI co-morbidities. This pilot study is a randomized, double blind, controlled trial of combination treatment (BCP + B. infantis) vs. BCP alone in a cross-over study in children ages 2-11 with ASD and GI co-morbidities (n = 8). This 12-week study included 5 weeks of probiotic-prebiotic supplementation, followed by a two-week washout period, and 5 weeks of prebiotic only supplementation. The primary outcome of tolerability was assessed using validated questionnaires of GI function and atypical behaviors, along with side effects. Results suggest that the combination treatment is well-tolerated in this cohort. The most common side effect was mild gassiness. Some participants on both treatments saw a reduction in the frequency of certain GI symptoms, as well as reduced occurrence of particular aberrant behaviors. Improvement may be explained by a reduction in IL-13 and TNF-α production in some participants. Although limited conclusions can be drawn from this small pilot study, the results support the need for further research into the efficacy of these treatments. PMID: 30625189 [PubMed - in process] View the full article

Google-The gut-brain connection: How psychotherapy treats irritable bowel syndrome - Baylor College of Medicine News

Jan 10, 2019
The gut-brain connection: How psychotherapy treats irritable bowel syndrome Baylor College of Medicine NewsWhat is the gut-brain connection? Baylor College of Medicine's Dr. Andrea Bradford explains why it's key to alleviating irritable bowel syndrome symptoms. View the full article

Twitter-RT @JBaruchMD: "There is a clear connection between #gender bias in medicine to something even more pervasive and fundamental in our societ…

Jan 9, 2019
RT @JBaruchMD: "There is a clear connection between #gender bias in medicine to something even more pervasive and fundamental in our societ… (RSS generated with FetchRss) View the full article

Twitter-Many people struggle with self-compassion, but it turns out that a kind, caring & warm attitude toward oneself can help those suffering with #chronicpain do the things they want to do according to new #research. Learn more via @PsyPost at http

Jan 9, 2019
Many people struggle with self-compassion, but it turns out that a kind, caring & warm attitude toward oneself can help those suffering with #chronicpain do the things they want to do according to new #research. Learn more via @PsyPost at https://www.psypost.org/2018/12/self-compassion-in-chronic-pain-sufferers-linked-to-a-better-capacity-to-continue-engaging-in-valued-activities-52775 #chronicillness (RSS generated with FetchRss) View the full article

Twitter-RT @ClevelandClinic: How a positive outlook can make a huge impact on your life: https://t.co/8ClIgBHmll

Jan 9, 2019
RT @ClevelandClinic: How a positive outlook can make a huge impact on your life: https://cle.clinic/2OZdCu0 (RSS generated with FetchRss) View the full article

Google-Doc: Small intestine bacteria unresponsive to treatment - The Detroit News

Jan 9, 2019
Doc: Small intestine bacteria unresponsive to treatment The Detroit NewsDear Dr. Roach: I have been suffering with small intestine bacterial overgrowth syndrome for five years. It started when I was treated for H. pylori with ... View the full article

Google-Gut Or Brain – Who's The Boss? - Star2.com

Jan 9, 2019
Gut Or Brain – Who's The Boss? Star2.comWhy does our tummy growl when we think of food or have 'butterflies' when we are nervous, whereas an upset tummy causes anxiousness or a bloated tummy ... View the full article

Google-New AGA opioid-induced constipation guidelines promote 'high-quality, high-value' care - Healio

Jan 9, 2019
New AGA opioid-induced constipation guidelines promote 'high-quality, high-value' care HealioThe American Gastroenterological Association released a clinical guideline on the management of opioid-induced constipation, informed by the most recent ... View the full article

Google-The Challenge of Diagnosing Abdominal Pain and Diarrhea - MedPage Today

Jan 9, 2019
The Challenge of Diagnosing Abdominal Pain and Diarrhea MedPage TodayDistinguishing between the myriad causes of intestinal symptoms such as abdominal pain, bloating, and persistent diarrhea can be challenging, especially in ... View the full article

Google-The Bristol Stool Chart Can Help You Tell If Your Poop Is Normal and Healthy - menshealth.com

Jan 9, 2019
The Bristol Stool Chart Can Help You Tell If Your Poop Is Normal and Healthy menshealth.comThe Bristol Stool Chart allows people with gastrointestinal symptoms such as constipation to clearly describe what their poop looks like and how healthy it is. View the full article

Google-FMT Addition Offers Better Outcomes in Recurrent C. Diff - MedPage Today

Jan 9, 2019
FMT Addition Offers Better Outcomes in Recurrent C. Diff MedPage TodayOnly one serious adverse event reported as possibly related to fecal microbiota transplantation-vancomycin combo. View the full article

Twitter-RT @CedarsSinaiLaur: New year, new test: @MarkPimentelMD of @CedarsSinai talks to FODMAP Everyday about better help for #IBS patients. Deta…

Jan 8, 2019
RT @CedarsSinaiLaur: New year, new test: @MarkPimentelMD of @CedarsSinai talks to FODMAP Everyday about better help for #IBS patients. Deta… (RSS generated with FetchRss) View the full article

Twitter-What’s the Difference Between #Fiber, #FODMAPs, and #Prebiotics? https://t.co/2tLD9ZCkU5

Jan 8, 2019
What’s the Difference Between #Fiber, #FODMAPs, and #Prebiotics? https://www.cookinglight.com/eating-smart/nutrition-101/difference-fiber-prebiotics-fodmaps?utm_source=twitter.com&utm_medium=social&utm_campaign=social-share-article (RSS generated with FetchRss) View the full article

Google-Beware of Pseudo-medicine - Pager Publications, Inc.

Jan 8, 2019
Beware of Pseudo-medicine Pager Publications, Inc.My social media, the internet and my guilty pleasure, Words with Friends, have been inundating me with advertisements showcasing this year's greatest deals ... View the full article

Twitter-Teenagers in the US are getting less than half of the recommended daily fiber, according to a recent study. Among other health concerns linked with low fiber is diverticulosis, a digestive condition in which pouches protrude from the colon. Lear

Jan 8, 2019
Teenagers in the US are getting less than half of the recommended daily fiber, according to a recent study. Among other health concerns linked with low fiber is diverticulosis, a digestive condition in which pouches protrude from the colon. Learn more at https://iffgd.org/other-disorders/diverticulosis-and-diverticulitis.html (RSS generated with FetchRss) View the full article

Google-Synbiotics may have dose-dependent effect against IBS symptoms: South Korean RCT - NutraIngredients-usa.com

Jan 8, 2019
Synbiotics may have dose-dependent effect against IBS symptoms: South Korean RCT NutraIngredients-usa.comSynbiotics can alleviate gastrointestinal symptoms and fatigue associated with irritable bowel syndrome (IBS), depending on the dosage administered, ... View the full article

Pubmed-A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.

Jan 8, 2019
Related Articles A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. Gastroenterol Hepatol. 2019 Jan 03;: Authors: Mearin F, Caballero AM, Serra J, Brotons C, Tantiñà A, Fort E, Martínez-Cerezo FJ, Perelló A, Sánchez-Antolín G, Rey E, Angós Musgo R, Berdier R, Gómez-Rodríguez B, Clavé P, García-Alonso M, Torán-Monserrat P, Tack J Abstract INTRODUCTION: The socioeconomic burden of irritable bowel syndrome with constipation (IBS-C) has never been formally assessed in Spain. PATIENTS AND METHODS: This 12-month (6-month retrospective and prospective periods) observational, multicentre study assessed the burden of moderate-to-severe IBS-C in Spain. Patients were included if they had been diagnosed with IBS-C (Rome III criteria) within the last 5 years and had moderate-to-severe IBS-C (IBS Symptom Severity Scale score [IBS-SSS] ≥175) at inclusion. The primary objective was to assess the direct cost to the Spanish healthcare system (HS). RESULTS: A total of 112 patients were included, 64 (57%) of which had severe IBS-C at inclusion. At baseline, 89 (80%) patients reported abdominal pain and distention. Patient quality of life (QoL), measured by the IBS-C QoL and EQ-5D instruments, was found to be impaired with a mean score of 59 and 57 (0-100, worst-best), respectively. Over the 6-month prospective period the mean IBS-C severity, measured using the IBS-SSS showed some improvement (315-234 [0-500, best-worst]). During the year, 89 (80%) patients used prescription drugs for IBS-C, with laxatives being the most frequently prescribed (n=70; 63%). The direct cost to the HS was €1067, and to the patient was €568 per year. The total direct cost for moderate-to-severe IBS-C was €1635. DISCUSSION: The majority of patients reported continuous IBS-C symptoms despite that 80% were taking medication to treat their IBS-C. Overall healthcare resource use and direct costs were asymmetric, with a small group of patients consuming the majority of resources. PMID: 30612850 [PubMed - as supplied by publisher] View the full article

Pages